Physician profile
Alan Merry
NPI 1265893390
$964.19
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $542 · 2022: $333 · 2023: $61.19 · 2024: $28.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $89.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $89.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $118.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $109.94 | 2022-2024 | |
| Glaxosmithkline, LLC. | $68.25 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $63.97 | 2021-2022 | |
| Daiichi Sankyo INC. | $53.72 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.81 | 2022 | |
| Incyte Corporation | $49.04 | 2021 | |
| Eisai INC. | $47.59 | 2023 | |
| Seagen INC. | $42.77 | 2021-2022 | |
| Beigene USA, INC. | $42.33 | 2021-2022 | |
| Amgen INC. | $34.91 | 2021 | |
| Karyopharm Therapeutics INC. | $31.57 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.89 | 2021-2022 | |
| Genzyme Corporation | $21.60 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $21.46 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $19.90 | 2021 | |
| Myovant Sciences INC. | $18.70 | 2022 | |
| Pharmacosmos Therapeutics INC. | $17.77 | 2021 | |
| Amag Pharmaceuticals, INC. | $17.66 | 2022 | |
| Blueprint Medicines Corporation | $17.37 | 2021 | |
| Dova Pharmaceuticals | $16.32 | 2021 | |
| Sobi, INC | $16.32 | 2022 | |
| Acceleron Pharma, INC. | $14.17 | 2021 | |
| Taiho Oncology, INC. | $13.40 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.06 | 2021 | |
| Stemline Therapeutics INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Merry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.